Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Telix Pharmaceuticals' TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell RCC
New Phase 3 ZIRCON analysis reveals TLX250-Px (Zircaix®) potential for diagnosing various kidney cancers, expanding beyond clear cell renal cell carcinoma applications.
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial, marking major milestone in synthetic lethality cancer treatment.
SAKIGAKE Designation Japan: Bispecific Antibodies for Leukemia Status 2026
This article delves into the SAKIGAKE Designation in Japan for bispecific antibodies, focusing on their potential to transform leukemia treatment by 2026.
Vector Science & Therapeutics Files Patent for Microneedle Catheter Platform for Cancer Drug Delivery
Vector Science & Therapeutics secures IP protection for novel microneedle catheter technology designed to deliver cancer drugs directly into tumors.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Huahui Health grants BeOne Medicines exclusive worldwide rights to develop HH160, a novel trispecific antibody for cancer immunotherapy treatment.
Genprex Receives Israel Patent for Reqorsa Gene Therapy Combined with PD-1 Antibodies in Cancer Treatment
Genprex secures Israeli patent protection for Reqorsa gene therapy combination with PD-1 antibodies, strengthening intellectual property portfolio for cancer treatment.
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
The NMPA Conditional Approval Pathway significantly enhances access to innovative oncology drugs, facilitating timely treatment options for cancer patients.
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Vivacta Biotechnology closes $50M+ Series A funding to advance GT801, an innovative in vivo CAR-T therapy for blood cancers and autoimmune diseases.
TLX597-Tx PSMA Radioligand Therapy Shows Promise in OPTIMAL-PSMA Trial for Early-Stage Prostate Cancer
TLX597-Tx radioligand therapy demonstrates low organ toxicity in OPTIMAL-PSMA trial, potentially enabling dose intensification for prostate cancer treatment.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
ImmunityBio hit with class action lawsuit after FDA determined company made false claims about Anktiva bladder cancer drug's capabilities beyond approved use.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.